Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial

<p><strong>Objectives:</strong> Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious...

Detaylı Bibliyografya
Asıl Yazarlar:	Kavanaugh, A, Coates, LC, Mease, PJ, Nowak, M, Hippeli, L, Lehman, T, Banerjee, S, Merola, JF
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Oxford University Press 2024

Benzer Materyaller

Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know?
Yazar:: Inês Pereira Amaral, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
Yazar:: Strand, V, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
Yazar:: Robert Roskoski, Jr.
Baskı/Yayın Bilgisi: (2023-03-01)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
Yazar:: Ana Martins, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Methotrexate in psoriasis and psoriatic arthritis
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Psoriatic arthritis
Yazar:: FitzGerald, O, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Measuring outcomes in psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Yazar:: Mease, PJ, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
Yazar:: Soriano, ER, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
Yazar:: Ian M. Catlett, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
Yazar:: Gladman, DD, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
Yazar:: Mease, P, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies
Yazar:: Mease, PJ, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
Yazar:: Mease, P, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Yazar:: Helliwell, PS, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Yazar:: Gossec, L, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Psoriatic arthritis: prospects for the future
Yazar:: Hackett, S, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Outcome measures in psoriatic arthritis: where next?
Yazar:: Hackett, S, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
Yazar:: S Banerjee, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
Yazar:: Taylor, PC, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

How should we define disease and outcomes in axial psoriatic arthritis?
Yazar:: Coates, LC
Baskı/Yayın Bilgisi: (2021)

Identification of psoriatic arthritis in patients with psoriasis
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study
Yazar:: Petersen, MB, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
Yazar:: Michaela Prchal-Murphy, ve diğerleri
Baskı/Yayın Bilgisi: (2015-11-01)

Classification and outcome measures for psoriatic arthritis
Yazar:: Leung, Y, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
Yazar:: Arianna Zhang, BS, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis
Yazar:: Zardin-Moraes, M, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
Yazar:: Bindu Murthy, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
Yazar:: Désirée van der Heijde, ve diğerleri
Baskı/Yayın Bilgisi: (2020-02-01)

Psoriatic arthritis in developing and resource-poor countries
Yazar:: Maharaj, AB, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage.
Yazar:: Zhi Li, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Yazar:: Neil J. Korman, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2023)